Related Experiment Video
Updated: Jun 2, 2026
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-γ plus
A Defaux1, M-G Zurich, P Honegger
1Department of Physiology, University of Lausanne, CH-1005 Lausanne, Switzerland.
Abstract:
Minocycline has been shown to inhibit microglia reactivity, and to decrease the severity and progression of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. It remained to be examined whether minocycline was also able to promote remyelination. In the present study, myelinating aggregating brain cell cultures were used as a model to study the effects of minocycline on microglial reactivity, demyelination, and remyelination. Cultures were treated simultaneously with two inflammatory agents, interferon-γ (IFN-γ) and lipopolysaccharide (LPS), which caused an inflammatory response accompanied by demyelination. The inflammatory response was characterized by microglial reactivity, upregulation of inflammatory cytokines and iNOS, and increased phophorylation of P38 and P44/42 mitogen activated protein (MAP) kinases. Minocycline inhibited microglial reactivity, and attenuated the increased phophorylation of P38 and P44/42 MAP kinases. Demyelination, determined by a decrease in myelin basic protein (MBP) content and immunoreactivity 48 h after the treatment with the inflammatory agents, was not prevented by minocycline. However, 1 week after demyelination was assessed, the MBP content was restored in presence of minocycline, indicating that remyelination was promoted. Concomitantly, in cultures treated with minocycline, the markers of oligodendrocyte precursors cells (OPCs) and immature oligodendrocytes NG2 and O4, respectively, were decreased compared to cultures treated with the inflammatory agents only. These results suggest that minocycline attenuates microglial reactivity and favors remyelination by enhancing the differentiation of OPCs and immature oligodendrocytes.
Insights
Minocycline reduces inflammation in brain cell cultures and promotes remyelination. This suggests potential therapeutic benefits for multiple sclerosis by enhancing oligodendrocyte differentiation.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Minocycline is known to inhibit microglia reactivity and reduce disease severity in experimental autoimmune encephalomyelitis, a multiple sclerosis model.
- Its potential to promote remyelination, a crucial process for recovery in demyelinating diseases, remained to be investigated.
Purpose of the Study:
- To investigate the effects of minocycline on microglial reactivity, demyelination, and remyelination using an in vitro model.
- To determine if minocycline could promote myelin repair after inflammatory-induced demyelination.
Main Methods:
- Myelinating brain cell cultures were exposed to inflammatory agents (interferon-gamma and lipopolysaccharide) to induce demyelination.
- Minocycline was administered to assess its impact on microglial activation, demyelination markers (myelin basic protein), and oligodendrocyte precursor cell (OPC) differentiation.
Main Results:
- Minocycline effectively inhibited microglial reactivity and attenuated inflammatory signaling pathways (MAP kinases).
- While minocycline did not prevent initial demyelination, it significantly promoted myelin repair (remyelination) as evidenced by myelin basic protein restoration.
- Minocycline treatment led to decreased markers of oligodendrocyte precursor cells (NG2) and immature oligodendrocytes (O4), suggesting enhanced differentiation.
Conclusions:
- Minocycline attenuates neuroinflammation by inhibiting microglial activation.
- Minocycline promotes remyelination, potentially by enhancing the differentiation of oligodendrocyte precursor cells into mature myelinating oligodendrocytes.
- These findings highlight minocycline's potential as a therapeutic agent for promoting myelin repair in demyelinating diseases like multiple sclerosis.
